Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2006-08-29
2006-08-29
Rawlings, Stephen L. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C514S015800, C424S185100, C424S277100
Reexamination Certificate
active
07098306
ABSTRACT:
A method for preventing or for treating cancer in a mammal, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface. The method comprises creating an immune response in the mammal to at least part of the amino acid sequence of an alpha fetoprotein molecule, where the immune response comprises activating alpha fetoprotein peptide specific T lymphocytes against the cancer cells, and where the part of the alpha fetoprotein molecule is selected from the group consisting of residues 137–145 of SEQ ID NO:2, and residues 325–334 of SEQ ID NO:2 and a combination of the preceeding.
REFERENCES:
patent: 0353 814 (1990-02-01), None
patent: 2005866 (1990-01-01), None
patent: A H2-218694 (1990-08-01), None
patent: WO 96/22787 (1998-08-01), None
Database UniProtKB Accession No. P02771 (printed from the Internet on Feb. 1, 2006), 6 pp.
Butterfield et al. (Expert Opin. Biol. Ther. 2002; 2 (2): 123-133).
Lollini et al. (Curr. Cancer Drug Targets. May 2005; 5 (3): 221-228).
Lollini et al. (Trends Immunol. Feb. 2003; 24 (2): 62-66).
Abelev et al. (Semin. Cancer Biol. Apr. 1999; 9 (2): 95-107).
Wang et al. (Exp. Opin. Biol. Ther. 2001; 1 (2): 277-290).
Bodey et al. (Anticancer Research. 2000; 20: 2665-2676).
Cox et al. (Science. 1994; 264: 716-719).
Ezzell (Journal of NIH Research. 1995; 7: 46-49).
Spitler (Cancer Biotherapy. 1995; 10: 1-3).
Boon (Advances in Cancer Research. 1992; 58: 177-210).
Arceci (Journal of Molecular Medicine. 1998; 76: 80-93).
Lee et al. (Journal of Immunology. 1999; 163: 6292-6300).
Zaks et al. (Cancer Research. 1998; 58: 4902-4908).
Gao et al. (Journal of Immunotherapy. 2000; 23: 643-653).
Hu et al. (Cancer Research. 1996; 56: 2479-2483).
Jaeger et al. (International Journal of Cancer. 1996; 66: 162-169).
Mukherji et al. (Proceedings of the National Academy of Science USA. 1995; 92: 8078-8082).
Bocchia et al. (Haematologica. 2000; 85; 1172-1206).
Gura (Science. 1997; 278: 1041-1042).
Reilly et al. (Curr. Opin. Investig. Drugs. Jan. 2001; 2 (1): 133-135).
Butterfield, L.H., et al.: “T cell responses to HLA-A* 0201-Restricted Peptides Derived from Human ′alpha! fetoprotein” Journal of Immunology Apr. 15, 2001 United States, vol. 166, No. 8, Apr. 15, 2001, pp. 5300-5308, XP002235963 ISSN: 0022-1767.
Morinaga T. et al., “Primary Structures of Human α-fetoprotein and Its MRNA,”Proc. Natl. Acad. Sci. USA, 80 (15), pp. 4604-4608 (1983).
Kazuo Sato et al., “Research on α-fetoprotein (VII),”Nihon University Journal of Medicine, 43 (10), pp. 835-842 (1984).
Hidematsu Hirai, “Diagnosis and Treatment of Liver Cancer by α-fetoproteins,”Seibutsu Butsuri Kagaku, 28 (6), pp. 333-341 (1984).
Taga, H., “The Effect of Active Immunization of Rats with Heterologous α-fetoprotein upon Hepatocarcinogenesis Induced by 3′-methyl-4-dimethylaminobenzene,”Gann, 74 pp. 1 248-257(1983).
Butterfield Lisa H.
Economou James S.
Ribas Bruguera Antoni
Farah David A.
Rawlings Stephen L.
Sheldon & Mak
The Regents of the University of California
LandOfFree
Method and compositions for treating hepatocellular cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and compositions for treating hepatocellular cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and compositions for treating hepatocellular cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3623484